LIXTE Biotechnology Holdings (NASDAQ: LIXT) is advancing the precision oncology landscape, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. “The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects,” reads a recent article. “By focusing on improving the therapeutic index of existing cancer modalities, the company is tackling a recurrent challenge in the field of oncology: maximizing treatment impact while cutting down risks to healthy tissue.”
To view the full article, visit https://ibn.fm/EE6ya
Questions around this news
What is LB-100 designed to do?
The release describes LB-100 as a small-molecule compound intended to complement chemotherapy and radiation by enhancing their efficacy. The company says the approach aims to improve treatment outcomes while limiting treatment-related effects on healthy tissue. It also reports that LB-100 has been well-tolerated in cancer patients at doses associated with anti-cancer activity.
Which cancer types are being studied in clinical trials of LB-100?
The release says proof-of-concept clinical trials are in progress for ovarian clear cell carcinoma and metastatic colon cancer. It does not provide trial enrollment, results, or timelines in the announcement. The company also describes preclinical research into LB-100’s potential to enhance chemotherapy and immunotherapy.
What is a PP2A inhibitor?
PP2A is a protein phosphatase, a type of enzyme that helps regulate cell activity by removing phosphate groups from proteins. A PP2A inhibitor reduces the activity of this enzyme. Researchers study such compounds for their possible effects on processes involved in disease, including cancer biology.
What does “therapeutic index” mean in cancer treatment?
Therapeutic index describes the relationship between a treatment’s beneficial effects and its harmful effects. In cancer care, improving it generally means seeking stronger control of cancer without a comparable increase in injury to healthy tissues. The concept helps frame efforts to make existing treatments more effective or better tolerated.
About LIXTE Biotechnology Holdings Inc.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com ), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for ovarian clear cell carcinoma and metastatic colon cancer.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Terms explained
- Precision oncology
- An approach to cancer care that uses information about a patient’s cancer, such as its biological features, to guide treatment choices.
- Small-molecule compound
- A molecule small enough to enter cells and interact with biological targets. Some small-molecule drugs are designed to change the activity of particular proteins or other cellular components.
- Therapeutic index
- A way of describing the balance between a treatment’s desired effects and its harmful effects. A wider margin between effective and harmful exposure is generally preferable.
- Preclinical data
- Findings from research conducted before a treatment is tested in clinical studies involving people. Such research can include laboratory experiments and studies in animals.
- Proof-of-concept clinical trial
- A clinical study designed to assess whether an intervention shows early evidence of producing its intended effect in people.
Earlier from LIXTE Biotechnology Holdings Inc.
- Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built
- LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference
- Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships
- LIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year
- LIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
